The ABC notes Starpharma as the Melbourne company developed the world’s first anti-viral condom using its VivaGel® active in the condom lubricant. VivaGel® has been shown to inactivate HIV, herpes, human papillomavirus and the Zika virus in laboratory studies.

 Go to the article (external link)

Starpharma is pleased to announce the VivaGel^® condom has been launched in Canada by Ansell under the LifeStyles^® Dual Protect^™ brand. 

Biotech Dispatch reports Starpharma’s recently completed its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis, noting that top-line results are expected in 2Q 2017.

 Go to the article (external link)

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced completion of its international, multicentre, phase 3 clinical studies evaluating VivaGel^® BV for the prevention of recurrent bacterial vaginosis (rBV). Starpharma expects topline results of the trials to be available in the second quarter of 2017.

Starpharma released its interim report and financial results for the half-year ended 31 December 2016.

Financial Summary

• Reported loss of $9.0M (Dec 2015: $10.0M)
• R&D tax incentives of $1.7M reported in the half-year (Dec 2015: $1.8M)
• Cash position at 31 December 2016 of $36.3M (June 2016: $46.0M)
• Receipt of $3.5M R&D tax incentive refund from FY16

Starpharma released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2016.

In this issue:

›› Enrolment completed for phase 3 program: VivaGel^® BV for prevention of recurrence

›› VivaGel^® BV granted QIDP and Fast Track designation by US FDA

›› Favourable revision to FDA guidance for BV Treatment

›› VivaGel^® condom approved in Canada; licensed in China and Iran

›› New DEP^® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies

›› DEP^® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2

›› DEP^® cabazitaxel shows no neutropenia

›› DEP^® irinotecan internal program shows superior performance

Download: Shareholder January 2017 (pdf file, 751kb)

The Australian reports that Bell Potter sees further upside for Starpharma, setting its share price target at $1.05, given the company had been granted Qualified Infectious Disease Product (QIDP) and fast track designation for VivaGel® BV by the US Food and Drug Administration.

 Go to the article (external link)

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel^® BV by the US Food and Drug Administration (FDA).

Starpharma Holdings Ltd today announced it has received the anticipated $3.5M of R&D tax incentive refund related to FY16 expenditures.